Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus

Trial Profile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs LY 3209590 (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 15 Dec 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2018.
    • 15 Dec 2017 Planned primary completion date changed from 1 May 2018 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top